Skip to main content
SpringerLink
Log in

Prevention of Type 1 Diabetes

  • Reference work entry
  • First Online:
Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment

Part of the book series: Endocrinology ((ENDOCR))

  • 3334 Accesses

Abstract

There is a genetic predisposition to type 1 diabetes (T1D), particularly conferred by alleles present within the major histocompatibility complex. In susceptible individuals, an environmental trigger initiates an immune response. The immune infiltration into pancreatic islets results in beta cell damage, impairment of beta cell function, and potential destruction of beta cells. Consequently, there have been a number of studies using immune intervention in an attempt to alter the natural history of the disease. These studies have been conducted both before clinical manifestations of T1D, in an attempt to prevent the evolution of the disease, and after the clinical onset of T1D, in an attempt to slow progressive loss of beta cell function. This chapter summarizes the most important clinical trials that have been conducted to date.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA) – DIAPREVENT. NCT00751842. www.ClinicalTrials.gov

  • Alhadj Ali M, Liu YF, Arif S, Tatovic D, Shariff H, Gibson VB, Yusuf N, Baptista R, Eichmann M, Petrov N, Heck S, Yang JHM, Tree TIM, Pujol-Autonell I, Yeo L, Baumard LR, Stenson R, Howell A, Clark A, Boult Z, Powrie J, Adams L, Wong FS, Luzio S, Dunseath G, Green K, O’Keefe A, Bayly G, Thorogood N, Andrews R, Leech N, Joseph F, Nair S, Seal S, Cheung H, Beam C, Hills R, Peakman M, Dayan CM. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med. 2017;9(402):pii:eaaf7779, 9 pp.

    Article  Google Scholar 

  • Ambery P1, Donner TW, Biswas N, Donaldson J, Parkin J, Dayan CM. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabet Med. 2014;31:399–402.

    Article  CAS  Google Scholar 

  • Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, Pozzilli P, for the DEFEND Investigator Group. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014;37:2746–54.

    Article  PubMed Central  Google Scholar 

  • Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7(315)

    Article  PubMed Central  Google Scholar 

  • Bonifacio E, Ziegler AG, Klingensmith G, Schober E, Bingley PJ, Rottenkolber M, Theil A, Eugster A, Puff R, Peplow C, Eisenbarth G, Hasford J, Achenbach P. The pre-POINT study group. Immune efficacy of high dose oral insulin for the primary prevention of type 1 diabetes in genetically-at-risk children: the primary oral insulin therapy (pre-POINT) study, a multicenter, double-blind, randomized, placebo-controlled clinical study. JAMA. 2015;313:1541–9.

    Article  CAS  Google Scholar 

  • Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, Bach JF. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med. 1988;318:663–70.

    Article  CAS  Google Scholar 

  • Bougneres PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, Chaussain JL, Bach JF. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes. 1990;39:1264–72.

    Article  CAS  Google Scholar 

  • Chase HP, Boulware D, Rodriguez H, Donaldson D, Chritton S, Rafkin LE, Krischer JP, Skyler JS, Clare-Salzler M, The Type 1 Diabetes TrialNet Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Study Group. Effect of docosahexaenoic acid (DHA) supplementation on infant inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes. Pediatr Diabetes. 2015;16:271–9.

    Article  CAS  Google Scholar 

  • Cook JJ, Hudson I, Harrison LC, Dean B, Colman PG, Werther GA, Warne GL, Court JM. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes. 1989;38:779–83.

    Article  CAS  Google Scholar 

  • Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, Martinez EZ, Foss MC, Burt RK, Voltarelli JC. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301:1573–9.

    Article  CAS  Google Scholar 

  • CTLA-4 Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus. ClinicalTrials.gov Identifier: NCT01773707. www.ClinicalTrials.gov

  • D’Addio F, Valderrama Vasquez A, Ben Nasr M, Franek E, Zhu D, Li L, Ning G, Snarski E, Fiorina P. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. Diabetes. 2014;63:3041–6.

    Article  Google Scholar 

  • Diabetes Prevention Trial – Type 1 Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346:1685–91.

    Article  Google Scholar 

  • Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J, DiAPREV-IT Study Group. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial. Pediatr Diabetes. 2017. https://doi.org/10.1111/pedi.12611. On-line ahead of print.

    Article  Google Scholar 

  • European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European nicotinamide diabetes intervention trial (ENDIT): a randomized controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363:925–31.

    Article  Google Scholar 

  • Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS, DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes. 2010;59:679–85.

    Article  CAS  Google Scholar 

  • Feutren G, Assan R, Karsenty G, Du Rostu H, Sirmai J, Papoz L, Vialettes B, Vexiau P, Rodier M, Lallemand A, Bach JF, For the Cyclosporin/Diabetes French Study Group. Cyclosporin increases the rate and length of remissions in insulin dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet. 1986;2(8499):119–24.

    Article  CAS  Google Scholar 

  • Freder1k-Study – Testing Infants for Type 1 Diabetes Risk. ClinicalTrials.gov Identifier: NCT03316261. www.ClinicalTrials.gov

  • Gerstein HC. Cow’s milk exposure and type I diabetes mellitus. A critical overview of the clinical literature. Diabetes Care. 1994;17:13–21.

    Article  CAS  PubMed Central  Google Scholar 

  • Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. 2011;34:2026–32.

    Article  PubMed Central  Google Scholar 

  • Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, the START Study Team. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: a randomized double-blind phase 2 trial. Lancet Diabetes Endocrinol. 2013;1:306–16.

    Article  CAS  PubMed Central  Google Scholar 

  • Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS, The Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new onset type 1 diabetes. Diabetes Care. 2010;33:826–32.

    Article  CAS  PubMed Central  Google Scholar 

  • Gottlieb PA, Alkanani AK, Michels AW, Lewis EC, Shapiro L, Dinarello CA, Zipris D. Alpha1-antitrypsin therapy downregulates toll like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes. J Clin Endocrinol Metab. 2014;99:E1418–26.

    Article  CAS  PubMed Central  Google Scholar 

  • Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014;2:710–8.

    Article  CAS  PubMed Central  Google Scholar 

  • Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC, Ludvigsson J, for the Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: 2-year results from the randomized, placebo-controlled protege trial. Diabetes 2013; 62:3901-3908.

    Article  CAS  PubMed Central  Google Scholar 

  • Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Investig. 2015;2015(125):448–55.

    Article  Google Scholar 

  • Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA, Shuster JJ, Zou B, Wasserfall CH, Posgai AL, Mathews CE, Brusko TM, Atkinson MA, Schatz DA. Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes. Diabetes. 2016;65:3765–75.

    Article  CAS  PubMed Central  Google Scholar 

  • Harrison LC, Colman PG, Dean B, Baxter R, Martin FI. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes. 1985;34:1306–8.

    Article  CAS  PubMed Central  Google Scholar 

  • Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1:295–305.

    Article  CAS  Google Scholar 

  • Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692–8.

    Article  CAS  Google Scholar 

  • Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54:1763–9.

    Article  CAS  PubMed Central  Google Scholar 

  • Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, the AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013a;62:3766–74.

    Article  CAS  PubMed Central  Google Scholar 

  • Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013b;56:391–400.

    Article  CAS  Google Scholar 

  • Hummel S, Pflüger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care. 2011;34:1301–5.

    Article  PubMed Central  Google Scholar 

  • Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus. ClinicalTrials.gov Identifier: NCT03428945. www.ClinicalTrials.gov

  • Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38:1964–74.

    Article  CAS  PubMed Central  Google Scholar 

  • Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352:2598–608.

    Article  CAS  Google Scholar 

  • Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, Vandemeulebroucke E, Van de Velde U, Crenier L, De Block C, Candon S, Waldmann H, Ziegler AG, Chatenoud L, Pipeleers D. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010;53:614–23.

    Article  CAS  Google Scholar 

  • Knip M, Virtanen SM, Seppä K, Ilonen J, Savilahti E, Vaarala O, Reunanen A, Teramo K, Hämäläinen AM, Paronen J, Dosch HM, Hakulinen T, Akerblom HK, Finnish TRIGR Study Group. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med. 2010;363:1900–8.

    Article  CAS  PubMed Central  Google Scholar 

  • Knip M, Åkerblom HK, Becker D, Dosch HM, Dupre J, Fraser W, Howard N, Ilonen J, Krischer JP, Kordonouri O, Lawson ML, Palmer JP, Savilahti E, Vaarala O, Virtanen SM, TRIGR Study Group. Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial. JAMA. 2014;311:2279–87.

    Article  PubMed Central  Google Scholar 

  • Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, Kolb H. The deutsche nicotinamide intervention study: an attempt to prevent type 1 diabetes. DENIS group. Diabetes. 1998;47:980–4.

    Article  CAS  Google Scholar 

  • Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008;359:1909–20.

    Article  CAS  Google Scholar 

  • Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, Veeze HJ, Palmer J. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med. 2012;366:433–42.

    Article  CAS  Google Scholar 

  • Malmegrim KC, de Azevedo JT, Arruda LC, Abreu JR, Couri CE, de Oliveira GL, Palma PV, Scortegagna GT, Stracieri AB, Moraes DA, Dias JB, Pieroni F, Cunha R, Guilherme L, Santos NM8, Foss MC, Covas DT, Burt RK, Simões BP, Voltarelli JC, Roep BO, Oliveira MC. Immunological Balance Is Associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes. Front Immunol 2017; 8:167.

    Google Scholar 

  • Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, Quattrin T. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care. 2009;32:1244–9.

    Article  CAS  PubMed Central  Google Scholar 

  • Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes. ClinicalTrials.gov Identifier: NCT03396484. www.ClinicalTrials.gov

  • Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett D, Wilson DM, Skyler JS, The Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill L, de Koning E, Ziegler A-G, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T, on behalf of the AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicenter, randomized double-masked, placebo-controlled trials. Lancet. 2013;381:1905–15.

    Article  CAS  Google Scholar 

  • Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008;372:1746–55.

    Article  Google Scholar 

  • Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP, Schatz D, Eisenbarth G. Diabetes prevention trial-type 1 study group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care. 2009;32:2269–74.

    Article  PubMed Central  Google Scholar 

  • Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, Tchao N, Sayre P, Bianchine P. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun. 2010;34:408–15.

    Article  CAS  PubMed Central  Google Scholar 

  • Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Skyler JS, The Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised double-blind, placebo-controlled trial. Lancet. 2011;378:412–9.

    Article  CAS  PubMed Central  Google Scholar 

  • Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Skyler JS, The Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up one year after cessation of treatment. Diabetes Care. 2014;37:1069–75.

    Article  CAS  PubMed Central  Google Scholar 

  • Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS, The Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion and preservation of Beta-cell function. N Engl J Med. 2009;361:2143–52.

    Article  CAS  Google Scholar 

  • Pescovitz MD, Greenbaum CJ, Bundy BN, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Skyler JS, The Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and Beta-cell function: two-year results. Diabetes Care. 2014;37:453–9.

    Article  CAS  PubMed Central  Google Scholar 

  • PINIT Study: Primary Intranasal Insulin Trial. ClinicalTrials.gov Identifier: NCT03182322. www.ClinicalTrials.gov

  • Pozzilli P, Raz I, Peled D, Elias D, Avron A, Tamir M, Eren R, Dagan S, Cohen IR. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed-meal. Diabetes Care. 2014;37:1384–91. Statement of Retraction. Diabetes Care 2015; 38:179.

    Article  CAS  Google Scholar 

  • Pre-POINT Early Study. ClinicalTrials.gov Identifier: NCT02547519. www.ClinicalTrials.gov

  • Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies (DiAPREV-IT2). ClinicalTrials.gov Identifier: NCT02387164. www.ClinicalTrials.gov

  • Raab J, Haupt F, Scholz M, Matzke C, Warncke K, Lange K, Assfalg R, Weininger K, Wittich S, Löbner S, Beyerlein A, Nennstiel-Ratzel U, Lang M, Laub O, Dunstheimer D, Bonifacio E, Achenbach P, Winkler C, Ziegler AG, Fr1da Study Group. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 2016;6(5):e011144.

    Article  PubMed Central  Google Scholar 

  • Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. ß-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet. 2001;358:1749–53.

    Article  CAS  PubMed Central  Google Scholar 

  • Raz I, Ziegler AG, Linn T, Schernthaner G, Bonnici F, Distiller LA, Giordano C, Giorgino F, de Vries L, Mauricio D, ProchaÅLzka V, Wainstein J, Elias D, Avron A, Tamir M, Eren R, Peled D, Dagan S, Cohen IR, Pozzilli P, The DIA-AID 1 writing group. Treatment of recent onset type 1 diabetes patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. Diabetes Care. 2014;37:1392–400. Statement of Retraction. Diabetes Care 2015; 38:178.

    Article  CAS  PubMed Central  Google Scholar 

  • Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR, The T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013;1:284–94.

    Article  CAS  PubMed Central  Google Scholar 

  • Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Investig. 2015;125:3285–96.

    Article  PubMed Central  Google Scholar 

  • Roep BO, Solvason N, Gottlieb PA, Abreu JR, Harrison LC, Eisenbarth GS, Yu L, Leviten M, Hagopian WA, Buse JB, von Herrath M, Quan J, King RS, Robinson WH, Utz PJ, Garren H, BHT-3021 Investigators, Steinman L. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci Transl Med. 2013;5(191):191ra82.

    Article  PubMed Central  Google Scholar 

  • Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG, Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487-497.

    Article  CAS  Google Scholar 

  • Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med. 1988;319:599–604.

    Article  CAS  PubMed Central  Google Scholar 

  • Skyler JS. Immune intervention studies in insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1987;3:1017–35.

    Article  CAS  PubMed Central  Google Scholar 

  • Skyler JS. Primary and secondary prevention of type 1 diabetes. Diabet Med. 2013a;30:161–9.

    Article  CAS  PubMed Central  Google Scholar 

  • Skyler JS. The compelling case for anti-CD3 in type 1 diabetes. Diabetes. 2013b;62:3656–7.

    Article  CAS  PubMed Central  Google Scholar 

  • Skyler JS. The prevention & reversal of type 1 diabetes – past challenges & future opportunities. Diabetes Care. 2015;38:997–1007.

    Article  Google Scholar 

  • Skyler JS, Marks JB. Immune intervention in type I diabetes mellitus. Diabetes Rev. 1993;1:15–42.

    Google Scholar 

  • Skyler JS, Rabinovitch A, The Miami Cyclosporine Diabetes Study Group. Cyclosporine in recent onset type I diabetes mellitus: effects on islet beta cell function. J Diabetes Complicat. 1992;6:77–88.

    Article  CAS  Google Scholar 

  • Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E, Diabetes Prevention Trial – Type 1 Diabetes Study Group. Effects of oral insulin in relatives of patients with type 1 diabetes mellitus. Diabetes Care. 2005;28:1068–76.

    Article  CAS  Google Scholar 

  • Skyler JS, Krischer JP, Becker DJ, Rewers M. Prevention of type 1 diabetes, Chapter 37. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, KMV N, Rewers M, Fradkin JE, editors. Diabetes in America. 3rd ed. Bethesda: National Institutes of Health, NIH Pub No. 17-1468; 2017. p. 37.1–21.

    Google Scholar 

  • Sosenko JM, Skyler JS, Herold KC, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the diabetes prevention trial-type 1. Diabetes. 2012;61:1331–7.

    Article  CAS  PubMed Central  Google Scholar 

  • Teplizumab for Prevention of Type 1 Diabetes in Relatives “At-Risk”. ClinicalTrials.gov Identifier: NCT01030861. www.ClinicalTrials.gov

  • The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes. 1988;37:1574–82.

    Article  Google Scholar 

  • Thrower SL, James L, Hall W, Green KM, Arif S, Allen JS, Van-Krinks C, Lozanoska-Ochser B, Marquesini L, Brown S, Wong FS, Dayan CM, Peakman M. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study. Clin Exp Immunol. 2009;155:156–65.

    Article  CAS  PubMed Central  Google Scholar 

  • Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes (INIT II). ClinicalTrials.gov Identifier: NCT00336674. www.ClinicalTrials.gov

  • TRIGR Study Group, Akerblom HK, Krischer J, Virtanen SM, Berseth C, Becker D, Dupré J, Ilonen J, Trucco M, Savilahti E, Koski K, Pajakkala E, Fransiscus M, Lough G, Bradley B, Koski M, Knip M. The trial to reduce IDDM in the genetically at risk (TRIGR) study: recruitment, intervention and follow-up. Diabetologia. 2011;54:627–33.

    Article  Google Scholar 

  • Vaarala O, Ilonen J, Ruohtula T, Pesola J, Virtanen SM, Härkönen T, Koski M, Kallioinen H, Tossavainen O, Poussa T, Järvenpää AL, Komulainen J, Lounamaa R, Akerblom HK, Knip M. Removal of bovine insulin from cow’s milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med. 2012;166:608–14.

    Article  Google Scholar 

  • Vandemeulebroucke E, Gorus F, Decochez K, Weets I, Keymeulen B, De Block C, Tits J, Pipeleers D, Mathieu C, The Belgian Diabetes Registry. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab. 2009;35:319–27.

    Article  CAS  Google Scholar 

  • Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simões BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297:1568–76.

    Article  CAS  Google Scholar 

  • Voltarelli JC, Martinez ED, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. Author’s reply. JAMA. 2009;302:624–5.

    Article  CAS  Google Scholar 

  • Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R. NBI-6024 study group. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care. 2009;32:2036–40.

    Article  CAS  PubMed Central  Google Scholar 

  • Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Raskin P, Rodriguez H, Russell WE, Schatz D, Wilson DM, Skyler JS, The Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011;378:319–27.

    Article  CAS  PubMed Central  Google Scholar 

  • Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA. 2017;318:1891–902.

    Article  PubMed Central  Google Scholar 

  • Writing Group for the TRIGR Study Group, Knip M, Åkerblom HK, Al Taji E, Becker D, Bruining J, Castano L, Danne T, de Beaufort C, Dosch HM, Dupre J, Fraser WD, Howard N, Ilonen J, Konrad D, Kordonouri O, Krischer JP, Lawson ML, Ludvigsson J, Madacsy L, Mahon JL, Ormisson A, Palmer JP, Pozzilli P, Savilahti E, Serrano-Rios M, Songini M, Taback S, Vaarala O, White NH, Virtanen SM, Wasikowa R. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: the TRIGR randomized clinical trial. JAMA. 2018;319:38–48.

    Article  PubMed Central  Google Scholar 

  • Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity. 2010;32:468–78.

    Article  CAS  PubMed Central  Google Scholar 

  • Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309:2473–9.

    Article  CAS  PubMed Central  Google Scholar 

  • Ziegler AG, Danne T, Dunger DB, Berner R, Puff R, Kiess W, Agiostratidou G, Todd JA, Bonifacio E. Primary prevention of beta-cell autoimmunity and type 1 diabetes – the global platform for the prevention of autoimmune diabetes (GPPAD) perspectives. Mol Metab. 2016;5:255–62.

    Article  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Research Institute, University of Miami, Miami, FL, USA

    Jay S. Skyler

Authors
  1. Jay S. Skyler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jay S. Skyler .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Diabetes and Metabolism, University and Hospital Trust of Verona, Verona, Italy

    Enzo Bonora

  2. Diabetes Division, Diabetes Research Unit, University of Texas Health Science Center, San Antonio, TX, USA

    Ralph A. DeFronzo

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Skyler, J.S. (2018). Prevention of Type 1 Diabetes. In: Bonora, E., DeFronzo, R. (eds) Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment . Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-45015-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-45015-5_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-45014-8

  • Online ISBN: 978-3-319-45015-5

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation